Delivery Order SPE2DB22D9225-SPE2DB24FR8FX

Award Date 9/26/24
Potential Completion Date 10/18/24
Potential Value $3.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $34,305.12 firm fixed-price delivery order is for the supply of NEXPLANON 68 MG IMPLANTS, with an ultimate completion date of August 9, 2024. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,288.14 firm fixed-price delivery order is for the supply of NEXPLANON 68 MG IMPLANTS, with a period of performance through September 3, 2024. DMS Pharmaceutical Group holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $10,720.35 firm fixed-price delivery order is for the supply of NEXPLANON 68 MG IMPLANTS and has an ultimate completion date of August 15, 2024. The contract is part of DMS Pharmaceutical Group's larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $5,554.48 firm fixed-price delivery order is for the supply of NEXPLANON 68 MG IMPLANTS and has an ultimate completion date of February 20, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $14,293.80, is a delivery order issued under DMS Pharmaceutical Group's existing $499,999,999 Indefinite Delivery Contract (IDC) with the DLA. The contract is for the delivery of 4,566,706,862 units of NEXPLANON 68 MG IMPLANTS, a specialized pharmaceutical product. The...
This federal contract award was made by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $6,837.40 firm fixed-price delivery order is for the supply of 4,561,965,899 units of NEXPLANON 68 MG IMPLANTS, with a final completion date of September 6, 2023. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,471.55 firm fixed-price delivery order is for the supply of NEXPLANON 68 MG IMPLANTS, a pharmaceutical product, with a period of performance through April 11, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The award, valued at $42,881.40, is a delivery order to provide NEXPLANON 68 MG IMPLANTS. The contract has a firm fixed-price pricing type and does not have a set-aside designation. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA valued...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $7,146.90 firm fixed-price delivery order is for the supply of NEXPLANON 68 MG IMPLANTS and has a period of performance through December 16, 2024. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $59,175.36 firm fixed-price delivery order is for NEXPLANON 68 MG IMPLANTS, with an ultimate completion date of October 5, 2022. The award is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This IDC allows...
  • SPE2DB22D9225
    Indefinite Delivery Contract
  • SPE2DB22D9225-SPE2DB24FR8FX
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $3,573.45 firm fixed-price delivery order is for the supply of NEXPLANON 68 MG IMPLANTS, with an ultimate completion date of October 18, 2024.

DMS Pharmaceutical Group Inc. holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. This award is issued under that overarching IDC vehicle, solidifying DMS Pharmaceutical Group's position as a critical supplier in the federal pharmaceutical supply chain. The contract has no set-aside designation.

Generated 12/26/24, 9:29 AM